The combined results highlight Cav-BC as an excellent candidate to be a subdomain of CSD active in the amelioration of lung fibrosis in vivo because it inhibits profibrotic features of monocytes as well as their migration and differentiation into fibrocytes. The gene discussed is CAV1; the disease is pulmonary fibrosis.